Barclays PLC Raises Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Barclays PLC increased its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 189.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 111,666 shares of the company's stock after purchasing an additional 73,127 shares during the period. Barclays PLC owned 0.12% of ARS Pharmaceuticals worth $1,618,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in shares of ARS Pharmaceuticals in the third quarter valued at about $30,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company's stock valued at $63,000 after acquiring an additional 4,472 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in ARS Pharmaceuticals during the 2nd quarter worth approximately $87,000. J.W. Cole Advisors Inc. grew its stake in shares of ARS Pharmaceuticals by 10.8% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company's stock valued at $131,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of ARS Pharmaceuticals in the third quarter valued at approximately $174,000. 68.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SPRY has been the topic of several recent research reports. William Blair raised shares of ARS Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Cantor Fitzgerald reiterated an "overweight" rating and set a $30.00 price target on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Finally, Leerink Partners raised their price objective on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a research report on Friday, September 20th. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $24.00.

Insider Activity

In other ARS Pharmaceuticals news, insider Sarina Tanimoto sold 100,000 shares of the business's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $11.67, for a total transaction of $1,167,000.00. Following the completion of the sale, the insider now owns 1,098,499 shares of the company's stock, valued at approximately $12,819,483.33. The trade was a 8.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder James E. Flynn sold 528,456 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $18.04, for a total value of $9,533,346.24. Following the completion of the transaction, the insider now owns 5,274,735 shares in the company, valued at approximately $95,156,219.40. This trade represents a 9.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,258,058 shares of company stock valued at $19,369,686 in the last 90 days. 40.10% of the stock is currently owned by insiders.

ARS Pharmaceuticals Stock Performance

NASDAQ SPRY traded down $0.36 during trading hours on Friday, hitting $10.79. 2,059,839 shares of the company's stock were exchanged, compared to its average volume of 849,313. The business's 50 day moving average is $13.91 and its 200-day moving average is $12.53. ARS Pharmaceuticals, Inc. has a 12-month low of $5.19 and a 12-month high of $18.51. The firm has a market capitalization of $1.05 billion, a P/E ratio of -21.16 and a beta of 0.88.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.